Keymed Biosciences Statistics

Total Valuation

Keymed Biosciences has a market cap or net worth of HKD 8.13 billion. The enterprise value is 6.17 billion.

Market Cap	8.13B
Enterprise Value	6.17B

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Keymed Biosciences has 275.60 million shares outstanding. The number of shares has increased by 0.22% in one year.

Current Share Class	n/a
Shares Outstanding	275.60M
Shares Change (YoY)	+0.22%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	25.09%
Float	184.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	87.93
PB Ratio	2.87
P/TBV Ratio	2.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-7.73
EV / Sales	70.32
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.42

Financial Position

The company has a current ratio of 4.98, with a Debt / Equity ratio of 0.28.

Current Ratio	4.98
Quick Ratio	4.68
Debt / Equity	0.28
Debt / EBITDA	n/a
Debt / FCF	-0.84
Interest Coverage	-49.47

Financial Efficiency

Return on equity (ROE) is -24.70% and return on invested capital (ROIC) is -14.63%.

Return on Equity (ROE)	-24.70%
Return on Assets (ROA)	-13.19%
Return on Invested Capital (ROIC)	-14.63%
Return on Capital Employed (ROCE)	-25.59%
Revenue Per Employee	78,616
Profits Per Employee	-715,435
Employee Count	927
Asset Turnover	0.02
Inventory Turnover	0.28

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -9.55% in the last 52 weeks. The beta is -0.01, so Keymed Biosciences's price volatility has been lower than the market average.

Beta (5Y)	-0.01
52-Week Price Change	-9.55%
50-Day Moving Average	34.57
200-Day Moving Average	35.50
Relative Strength Index (RSI)	44.89
Average Volume (20 Days)	1,365,820

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Keymed Biosciences had revenue of HKD 87.74 million and -798.43 million in losses. Loss per share was -3.06.

Revenue	87.74M
Gross Profit	60.23M
Operating Income	-892.34M
Pretax Income	-789.60M
Net Income	-798.43M
EBITDA	-816.29M
EBIT	-892.34M
Loss Per Share	-3.06

Full Income Statement

Balance Sheet

The company has 2.77 billion in cash and 807.31 million in debt, giving a net cash position of 1.96 billion or 7.12 per share.

Cash & Cash Equivalents	2.77B
Total Debt	807.31M
Net Cash	1.96B
Net Cash Per Share	7.12
Equity (Book Value)	2.83B
Book Value Per Share	10.28
Working Capital	2.39B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -762.01 million and capital expenditures -198.50 million, giving a free cash flow of -960.52 million.

Operating Cash Flow	-762.01M
Capital Expenditures	-198.50M
Free Cash Flow	-960.52M
FCF Per Share	-3.49

Full Cash Flow Statement

Margins

Gross Margin	68.65%
Operating Margin	-1,017.07%
Pretax Margin	-899.98%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Keymed Biosciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.22%
Shareholder Yield	-0.22%
Earnings Yield	-9.82%
FCF Yield	-11.81%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Keymed Biosciences has an Altman Z-Score of 3.47.

Altman Z-Score	3.47
Piotroski F-Score	n/a